Chalfont St Giles, UK – 28 November 2017 – GE Healthcare has completed the acquisition of Puridify, a bioprocessing SME that is developing a nanofiber-based platform purification technology for biopharmaceutical production. Puridify’s technology, FibroSelect, is complementary to the bead resins and chromatography membranes used today in downstream bioprocessing, promising faster mass transfer, scalability and ease of use.
Calling practically minded, hands-on designers and engineers. Come and join our tools and device design team to develop our new products.
Oliver Hardick, CEO, presents at ECI: Single-use Technologies II in the Poster Session with a presentation “Single-Use Primary Capture Technology with the Promise to Deliver New Standards for the Economics, Convenience and Reliability of mAb Bioprocessing”
Bioprocess International May 2017 edition – Cheryl Scott, Oliver Hardick & Will Lewis – Disposables Enable the Integration of Upstream and Downstream Processing
Krunal Mehta, Amgen, presents is work with Puridify’s FibroSelect Technology in a talk titled “Evaluation of Single-use FibroSelect Technology for Monoclonal Antibody purification”.
Iwan Roberts, Puridify COO, presents at ACS 2017 in the “Downstream Processes” session with his talk “Combining cell removal and Protein A affinity separation in the same unit operation”.
London, UK – 5 December 2016 – Puridify Limited (“Puridify”), developers of novel bioprocessing purification technologies for industrial biomolecule manufacture, today announced the signing of an 18 month collaboration with GlaxoSmithKline (“GSK”) to extend the evaluation of Puridify’s FibroSelect purification technology with a view to building a package to support potential use of nanofibres in toxicology and clinical manufacture.
London, UK – 21 October 2016 – Puridify Limited (“Puridify”), a developer of novel bioprocessing purification technologies for industrial biomolecule manufacture, has won a 2016 BioProcess International Award for best collaboration with GlaxoSmithKline to advance industrial evaluation of Puridify’s FibroSelect.
London, UK – 30 September 2016 – Puridify Limited (“Puridify”), developers of novel bioprocessing purification technologies for industrial biomolecule manufacture, has been announced as a finalist for two BioProcess International Awards. These prestigious industry awards recognize the outstanding people, organizations, and technologies that define excellence and that have changed the status-quo by enabling more effective, less expensive biotherapeutic development and manufacturing.